Legato puts AI hearing glasses on sale in the U.S. starting at $999

Legato said Thursday Legato Frames are available in the United States starting at $999 online at legatohearing.com, with select eyecare providers coming soon — FDA-regulated over-the-counter hearing aids built into prescription-ready eyewear for adults with mild-to-moderate hearing loss.

Most adults who could use hearing aids still don’t, often because the device looks and feels like a medical appliance. Putting FDA-regulated over-the-counter hearing AI into glasses people already wear is a same-day test of whether better hearing can ship as eyewear at $999 instead of another behind-the-ear stigma tax.

On Thursday, 1 October 2026, Legato said its flagship product, Legato Frames, is available in the United States. The starting price is $999. A buyer can order online at legatohearing.com. The company says select eyecare providers nationwide will offer the glasses soon, and that they will often be eligible for coverage by vision insurance. Often is the company’s word. It is not a promise that a particular plan pays. The glasses are for adults with up to moderate hearing loss. Legato says they are the first device to put AI-powered hearing aids and prescription lenses in one pair. The dateline is Boston. GlobeNewswire carries the release. The page prints October 01, 2026, 09:00 ET, which is 9:00 a.m. Eastern. The source line is Legato. Those lines are the release.

Why Legato says the category is still mostly empty. More than 1.5 billion people worldwide live with hearing loss. In the United States, the release says, an estimated 50 million adults have recognized hearing loss, yet 80 percent of those who could benefit from hearing aids do not use them. Eighty percent is four in five. The release ties that gap to cost, comfort, and stigma. Stigma, here, is the feeling that a hearing aid looks like a medical appliance. The 50 million and the 80 percent are two figures the release prints side by side. It does not say the 80 percent is a slice of the 50 million, and it does not print the study behind either number. Those lines are Legato’s.

The release also cites a finding about hearing and the brain, and that finding is not a Legato trial. A meta-analysis of more than 126,000 people across eight long-term studies, cited in the 2024 Lancet Commission report on dementia, found that people with hearing loss who used a hearing device had nearly a 20 percent lower risk of cognitive decline and a 17 percent lower risk of dementia than those who did not. A meta-analysis pools earlier studies. Nearly 20 percent is a bit under one in five. Seventeen percent is a bit under one in six. Cognitive decline is a drop in memory and thinking. Dementia is the more serious loss of those abilities. The release says these findings show hearing care matters for healthy aging, and that Frames give adults another way to hear clearly without giving up style, convenience, or comfort. Those sentences are Legato’s account of the Lancet Commission citation. They are not a claim that Frames themselves were measured in those eight studies. The company homepage states the same 2024 Lancet Commission review with slightly different figures: more than 125,000 people, followed for 2 to 25 years, and about 20 percent lower risk of cognitive decline, with the same 17 percent dementia line. The homepage also says the Commission named hearing loss the top modifiable risk factor for dementia, ahead of smoking, blood pressure, and obesity. Modifiable means a person can change it. That ranking line is the homepage’s. It is not in the October 1 release.

What the glasses are, as the release describes them. Frames come in three styles. One is Aria, an acetate-and-metal browline, the thick upper rim over a thinner lower rim that high-end glasses use. The release says each style uses premium materials and advanced Pentax lenses, and that the hearing technology sits in the arms so the pair still looks like everyday eyewear. The frames take prescription lenses. They stream music and calls over Bluetooth on iPhone and Android. Bluetooth is the short-range radio link a phone already uses for headphones. The product page splits the starting price by style. Aria starts at $1,099. Symphony and Harmony each start at $999. The release’s “starting at $999” matches the two lower styles. The page’s comparison table says the line starts from $999 for the glasses-and-hearing combination, against an average of $3,400 or more for prescription hearing solutions. That average is the page’s. The release says some of the aids in a separate lab ranking cost thousands more. It does not print $3,400.

SpeechSense is the hearing software, as the release names it. Legato calls it patented AI hearing-processing technology. It separates speech from background noise and enhances the speech in real time, so a conversation can come through in a crowded room. All of that processing happens on the glasses. The release says there are no cameras and no recording. The open-ear design leaves the ear canal clear, so the wearer hears the conversation and still hears the room. Open-ear means the speaker does not plug the ear. The lightest pair, with lenses, weighs as little as 34 grams. Thirty-four grams is about 1.2 ounces, in the range of a pair of glasses rather than a separate earpiece. Battery life is 10 to 12 hours. The release also includes free lifetime support from a U.S.-based team of audiologists and product specialists. An audiologist is a licensed hearing professional. The product page adds steps the release does not print. Opening the arms turns the glasses on. The Legato app is where a wearer fine-tunes the sound. The page offers a 45-day money-back guarantee and a warranty of up to three years. Those trial, app, and warranty lines are the page’s.

The lab score, as Legato reports it. HearAdvisor, which the release calls a leading audiology lab, scores hearing devices across dozens of sound environments and turns that into one SoundScore. In May 2026 testing, Legato says, Frames earned 4.6 out of 5 and ranked among the top 10 devices HearAdvisor tested, including over-the-counter aids and prescription aids that cost thousands more. 4.6 out of 5 is high on that lab’s scale. Top 10 is a rank inside the devices that lab tested, not a claim that Frames beat every aid on the market. The release does not print the full list, and it does not say the Food and Drug Administration scored the glasses. The product page says Frames were independently benchmarked as a top-performing hearing device, and that results vary widely by brand and model. The page does not print the 4.6. The score and the May 2026 date stay with the release, which is Legato citing HearAdvisor.

Mehul Trivedi, chief executive and co-founder, is quoted on the release. “We started Legato because we fundamentally believe that people deserve better choices for hearing care,” he said. “There are millions of people who want to hear better, but remain on the sidelines because they have not found a product they actually want to wear. We want to change that.” That quotation is his, in the release.

Who the company says it is. In August 2026, Legato emerged from stealth with $12 million from Neotribe Ventures, Listen, and Village Global. Stealth means the company was working before it announced itself. Twelve million dollars is that earlier raise. The October release says the money was to create a new category of hearing technology. It does not say how much of the $12 million is still in the bank, and it does not print a valuation. The about box says Legato was founded in 2024 by Mehul Trivedi and Steve Romine. Trivedi led the creation of Bose Frames audio glasses and later ran smart eyewear at EssilorLuxottica. Romine launched Bose SoundControl hearing aids and later ran the consumer and retail businesses at Audicus. The about box says Legato is moving hearing care from a medical device that is hard to adopt to a product people are willing to wear every day. The homepage tells a shorter version of the same origin. It quotes Romine, “Hearing aids went 70 years without a real update,” and says the two founders built Bose Frames, launched the first over-the-counter hearing aid, and lobbied the Food and Drug Administration to create that category. Lobbied, on that page, means they pushed the agency to make the category. That sentence is the homepage’s. The October about box names Bose Frames, EssilorLuxottica, Bose SoundControl, and Audicus. It does not say they wrote the over-the-counter rule.

What the release says about regulation, and what it does not say. Legato Frames are FDA-regulated over-the-counter hearing aids for adults with mild-to-moderate hearing loss. The release says they were designed and manufactured in accordance with FDA requirements for safety, performance, labeling, and consumer protections. Over-the-counter, here, means an adult can buy them without a prescription for a hearing aid. Mild-to-moderate is the hearing-loss range the release names. The release does not print a clearance number, a study of Frames against a named prescription aid, or a list of insurers that pay. The glasses are on sale now at legatohearing.com. Press inquiries go to press@legatohearing.com.

The picture is Legato’s Aria product photo, a three-quarter studio shot of the acetate-and-metal browline on a white field, with a dark margin around it. A black bar along the bottom reads “Legato Frames Aria · SpeechSense AI · from $999.” The $999 on that bar is the starting price the company printed for the line. The product page lists Aria itself at $1,099. The photo does not print a calendar date.

In plain terms, Legato said on Thursday that Frames, its AI hearing glasses, are on sale in the United States starting at $999, with eyecare shops to follow. SpeechSense runs on the glasses, with no camera and no recording, and the company cites a May 2026 HearAdvisor SoundScore of 4.6 out of 5. The release calls them FDA-regulated over-the-counter hearing aids for mild-to-moderate loss. It does not print a clearance number. The product page prices Aria at $1,099 and Symphony and Harmony at $999. The hearing-and-dementia figures are Legato’s citation of the 2024 Lancet Commission, not a trial of these glasses.